Amino acid uptake measured by [18F]AFETP increases in response to arginine starvation in ASS1-deficient sarcomas by Prudner, Bethany Cheree et al.




Amino acid uptake measured by [18F]AFETP
increases in response to arginine starvation in
ASS1-deficient sarcomas
Bethany Cheree Prudner
Washington University School of Medicine in St. Louis
Fangdi Sun
Washington University School of Medicine in St. Louis
Jeffrey Charles Kremer
Washington University School of Medicine in St. Louis
Jinbin Xu
Washington University School of Medicine in St. Louis
Chaofeng Huang
Washington University School of Medicine in St. Louis
See next page for additional authors
Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs
This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open
Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact engeszer@wustl.edu.
Recommended Citation
Prudner, Bethany Cheree; Sun, Fangdi; Kremer, Jeffrey Charles; Xu, Jinbin; Huang, Chaofeng; Solingapuram Sai, Kiran Kumar;
Morgan, Zachary; Leeds, Hayden; McConathy, Jonathan; and Van Tine, Brian Andrew, ,"Amino acid uptake measured by
[18F]AFETP increases in response to arginine starvation in ASS1-deficient sarcomas." Theranostics.8,8. . (2018).
https://digitalcommons.wustl.edu/open_access_pubs/6693
Authors
Bethany Cheree Prudner, Fangdi Sun, Jeffrey Charles Kremer, Jinbin Xu, Chaofeng Huang, Kiran Kumar
Solingapuram Sai, Zachary Morgan, Hayden Leeds, Jonathan McConathy, and Brian Andrew Van Tine
This open access publication is available at Digital Commons@Becker: https://digitalcommons.wustl.edu/open_access_pubs/6693






2018; 8(8): 2107-2116. doi: 10.7150/thno.22083 
Research Paper 
Amino Acid Uptake Measured by [18F]AFETP Increases 
in Response to Arginine Starvation in ASS1-Deficient 
Sarcomas 
Bethany Cheree Prudner1*, Fangdi Sun1,2*, Jeffrey Charles Kremer1, Jinbin Xu3, Chaofeng Huang3, Kiran 
Kumar Solingapuram Sai3, Zachary Morgan3, Hayden Leeds3, Jonathan McConathy3,4,5 , Brian Andrew 
Van Tine1,4 
1. Division of Medical Oncology, Department of Internal Medicine, Washington University School of Medicine, St. Louis, MO, 63110, USA 
2. Harvard Medical School, Cambridge, MA, 02115, USA 
3. Department of Radiology, Washington University School of Medicine, St. Louis, MO, 63110, USA 
4. Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO, 63110, USA 
5. Department of Radiology, University of Alabama at Birmingham, AL, 35249, USA 
*There authors contributed equally to this work 
 Corresponding authors: Brian A. Van Tine, M.D., Ph.D., 660 S Euclid, Campus Box 8007, St. Louis, MO 63110, Office: 314.747.8475; Fax: 314.747.9320; Email: 
bvantine@wustl.edu and Jonathan McConathy, MD., Ph.D., 619 19th St. South, JT 773, Birmingham, AL 35249, E-mail: jmcconathy@uabmc.edu  
© Ivyspring International Publisher. This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license 
(https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions. 
Received: 2017.07.25; Accepted: 2018.02.13; Published: 2018.03.07 
Abstract 
Rational: In a subset of cancers, arginine auxotrophy occurs due to the loss of expression of 
argininosuccinate synthetase 1 (ASS1). This loss of ASS1 expression makes cancers sensitive to arginine 
starvation that is induced by PEGylated arginine deiminase (ADI-PEG20). Although ADI-PEG20 
treatment is effective, it does have important limitations. Arginine starvation is only beneficial in patients 
with cancers that are ASS1-deficient. Also, these tumors may metabolically reprogram to express ASS1, 
transforming them from an auxotrophic phenotype to a prototrophic phenotype and thus rendering 
ADI-PEG20 ineffective. Due to these limitations of ADI-PEG20 treatment and the potential for 
developing resistance, non-invasive tools to monitor sensitivity to arginine starvation are needed.  
Methods: Within this study, we assess the utility of a novel positron emission tomography (PET) tracer 
to determine sarcomas reliant on extracellular arginine for survival by measuring changes in amino acid 
transport in arginine auxotrophic sarcoma cells treated with ADI-PEG20. The uptake of the 18F-labeled 
histidine analogue, (S)-2-amino-3-[1-(2-[18F]fluoroethyl)-1H-[1,2,3]triazol-4-yl]propanoic acid (AFETP), 
was assessed in vitro and in vivo using human-derived sarcoma cell lines. In addition, we examined the 
expression and localization of cationic amino acid transporters in response to arginine starvation with 
ADI-PEG20. 
Results: In vitro studies revealed that in response to ADI-PEG20 treatment, arginine auxotrophs increase 
the uptake of L-[3H]arginine and [18F]AFETP due to an increase in the expression and localization to the 
plasma membrane of the cationic amino acid transporter CAT-1. Furthermore, in vivo PET imaging studies 
in mice with arginine-dependent osteosarcoma xenografts showed increased [18F]AFETP uptake in 
tumors 4 days after ADI-PEG20 treatment compared to baseline.  
Conclusion: CAT-1 transporters localizes to the plasma membrane as a result of arginine starvation 
with ADI-PEG20 in ASS1-deficient tumor cells and provides a mechanism for using cationic amino acid 
transport substrates such as [18F]AFETP for identifying tumors susceptible to ADI-PEG20 treatment 
though non-invasive PET imaging techniques. These findings indicate that [18F]AFETP-PET may be suitable 
for the early detection of tumor response to arginine depletion due to ADI-PEG20 treatment. 










Sarcomas are a rare and diverse group of 
malignancies with over 60 subtypes that arise from 
mesenchymal origin that can result in tumors of bone, 
muscle, cartilage or connective tissue (1, 2). In spite of 
advances in identifying and understanding the 
functional importance of genetic abnormalities within 
these tumors, cytotoxic chemotherapy still remains 
the standard of care for most locally advanced and 
metastatic sarcomas (3, 4). The risk of relapse remains 
high at 50%, with most of these representing 
metastatic failures with an overall survival of 12-14 
months (1, 3). Despite the wide range of different 
subtypes within sarcoma, the silencing of arginine-
succinate synthase 1 (ASS1) is found in approximately 
90% of all sarcoma cases and is the most commonly 
altered gene in sarcoma (5). This silencing leads to 
ASS1 as a potential biomarker in several cancers (6, 7). 
As a result of the poor prognosis and very few 
available agents in sarcoma, there is a need for the 
development of new treatment strategies, including 
therapies based on sarcoma metabolism (1, 3, 5). 
Dysregulation of tumor metabolism is emerging 
as a key event in cancer growth and tumorigenesis (8). 
The lack of ASS1 renders the tumors arginine 
auxotrophs, requiring exogenous arginine for cellular 
processes including growth, proliferation, and 
survival. Arginine is a semi-essential amino acid: 
although de novo synthesis can occur, it is not enough 
to maintain plasma levels of this amino acid, and so 
the main source for arginine is through dietary intake 
when ASS1 is deficient (9). Arginine is required for 
protein synthesis as well as an array of biosynthetic 
pathways including the synthesis of nitric oxide (NO), 
polyamines, and agmatine as well as the transaminat-
ion of the amino acids proline and glutamate (10). 
ASS1 loss has been associated with decreased overall 
survival in ovarian cancer and myxoid fibrosarcoma, 
as well as reduced metastatic-free survival in 
osteosarcoma, implicating a tumor suppressor 
function for this metabolic gene (11-13). Exploiting the 
switch to arginine auxotrophy has led to clinical 
anticancer treatments where PEGylated arginine 
deiminase (ADI-PEG20) is used as an arginine- 
depleting therapy that induces nutrient starvation by 
enzymatically converting arginine to citrulline (7, 
14-17). Recently it has been shown that this induced 
arginine starvation by ADI-PEG20 alters tumor 
metabolism by decreasing the tumor’s dependence on 
the Warburg effect and increasing its dependence on 
oxidative phosphorylation (18).  
When de novo arginine biosynthesis cannot occur 
due to the lack of ASS1 expression, cells need to 
transport arginine across the plasma membrane to 
maintain cellular functions, such as protein synthesis 
and proliferation (19, 20). Several families of 
specialized biological transporter systems can 
mediate the uptake of L-arginine and other cationic 
amino acids from the extracellular space including 
systems y+, b0,+AT, ATB0,+ and y+L. These transporters 
differ in mechanism of transport and specificity for 
cationic amino acids. The y+ transport system is 
widely expressed and considered to be the major 
arginine transporter in most tissues and cells (21, 22). 
System y+ activity is mediated by three different 
cationic amino-acid transporter proteins: (CAT)-1, 
CAT-2A/2B, and CAT-3, which are characterized by 
high affinity for cationic amino acids, sodium 
independence, and facilitated transport dependent on 
the intracellular substrate composition (23-25). 
Hatzoglou et al. showed that CAT-1 stability and 
translation increases when there is a limitation of 
amino acids (26). Finally, CAT-1 was implicated as the 
transporter in AML responsible for arginine uptake 
(27, 28), a finding that has not been investigated 
outside of AML. 
Therefore, we hypothesized that arginine 
starvation will induce an increase in the expression 
and localization to the plasma membrane of an 
arginine transporter system, resulting in the 
augmentation of extracellular arginine uptake. 
Furthermore, we sought to exploit this biological 
response using the radiolabeled amino acid 
(S)-2-amino-3-[1-(2-[18F]fluoroethyl)-1H-[1,2,3]triazol-
4-yl]propanoic acid (AFETP) as a positron emission 
tomography (PET) imaging agent to detect the 
upregulation of amino acid transport by tumor cells 
deprived of extracellular arginine. [18F]AFETP is 
structurally similar to the natural amino acid 
L-histidine and enters cells in part through the 
cationic amino acid transporters (29, 30). Previous 
studies have shown promising imaging properties in 
rodent models of high grade glioma. These properties 
make [18F]AFETP well-suited to non-invasively 
monitor changes in cationic amino acid transport 
through small animal PET in mice with the potential 
for clinical translation for imaging this phenomenon 
in cancer patients (29). As ASS1-deficient tumors 
exposed to ADI-PEG20 monotherapy develop 
resistance through the re-expression of ASS1, 
[18F]AFETP-PET could be a useful clinical tool in 
patients being treated with ADI-PEG20 for early 
response evaluation and to detect the development of 
resistance to ADI-PEG20 therapy (5, 31).  
Results 
Sarcoma cell lines frequently lack expression 
of ASS1 
As the lack of ASS1 expression is generally 





associated with sensitivity to ADI-PEG treatment, 
expression levels were assessed in human sarcoma 
tumors (5). Bean et al. revealed that approximately 
90% of sarcoma tumors have decreased or loss of 
ASS1 expression. To further expand on the 
immunohistochemical analysis that showed a 
frequent loss of ASS1 expression in sarcoma human 
tumors, a panel of sarcoma cell lines were assessed for 
the expression status of ASS1. Western blot analysis 
revealed that ASS1 is not significantly expressed in 
the SKLMS1 cell line and is expressed to a lesser 
extent in MNNG as compared to MG63, a cell line 
resistant to treatment with ADI-PEG20 (5). 
Furthermore, ASS1 expression was either increased or 
expressed upon ADI-PEG20 treatment (Fig 1A). The 
effect of ADI-PEG20 on cell growth, in vitro, was 
assessed in both ASS-positive sarcoma cell lines and 
those lacking expression of the enzyme. A clear 
correlation of ASS1 expression with or without 
ADI-PEG treatment on cell growth was observed. For 
the ASS1-negative sarcoma cell lines, SKLMS1 and 
MNNG, cell growth was arrested in comparison with 
the ASS1-positive MG63 cell line when they were 
treated with ADI-PEG20 (Fig 1B; mean ± SD (%) for 
untreated cells: 100 ± 4.8 (SKLMS1),100 ± 1.5 
(MNNG), 100 ± 5.1 (MG63) vs. ADI-PEG20-treated 
cells: 40 ± 4.5 (SKLMS1), 51 ± 1.8 (MNNG), 98 ± 4.9 
(MG63). In ASS1-negative cell lines unable to make 
arginine, normalized L-[3H]arginine uptake increased 
by 2.1 ± 0.8 fold (SKLMS1) and 3.2 ± 0.5 fold (MMNG) 
compared to control conditions after 72 hours of 
ADI-PEG20 treatment while the ASS1-positive cell 
line MG63 showed a 0.7 ± 0.2 fold change in 
normalized L-[3H]arginine uptake with ADI-PEG20 
treatment (see Fig 1C). Taken together, these results 
identify a subpopulation of sarcoma cell lines that are 
arginine auxotrophs due to the decreased enzymatic 
activity of ASS1.  
Protein expression of cationic amino acid 
transporters in sarcoma cell lines  
Due to the increased uptake of arginine in the 
ASS1-deficient cell lines upon arginine deprivation, 
the question of whether the expression levels of 
cationic amino acid transporters changed relative to 
ADI-PEG20 treatment in sarcoma cell lines was 
addressed. Immunoblot analysis of seven transp-
orters, CAT-1, CAT-2, CAT-3, y+LAT1, y+LAT2, bo+AT 
and ATB0+0, demonstrated that only CAT-1 trans-
porter expression was increased in response to ADI- 
PEG20 treatment, whereas CAT-2, CAT-3, y+LAT1, 
y+LAT2, bo+AT and ATB0,+ expression levels were 
found to remain constant or decrease upon arginine 
starvation (Fig 2). CAT-1 protein expression was also 
found to increase in MG63 in response to extracellular 
arginine depletion with ADI-PEG20, but this finding 
did not correlate with increased extra-
cellular L-[3H]arginine uptake (Fig 1C). 
 Membrane localization of the 
cationic amino acid transporters 
in sarcoma cell lines by IF 
As only CAT-1 protein expression 
changed expression pattern in response 
to arginine starvation, we examined the 
subcellular localization of the y+ 
transporters in response to ADI-PEG20 
treatment using semi-quantitative 
immunofluorescence labeling (32). In 
response to ADI-PEG20 treatment, 
CAT-1 was observed to alter its localiz-
ation, with increased abundance seen at 
the plasma membrane (Fig 3). Though 
CAT-3 expression could not be reliably 
determined by IF after multiple 
attempts, the other five cationic amino 
acid transporters examined were not 
dramatically altered by ADI-PEG20 
treatment (Fig 3). This demonstrates 
that CAT-1 is the critical arginine trans-
porter implicated in the response to 




Figure 1. ASS1 levels correlate with ADI-PEG20 response in sarcoma cell lines. (A) 
Western blot analysis of ASS1 expression in SKLMS1, MNNG and MG63 cell lines in the presence of 
ADI-PEG20 treatment (72 h). Actin was used as a loading control. (B) Total cell count of SKLMS1, 
MNNG and MG63 after 72 h of ADI-PEG20 treatment. The total percentage of cells was normalized 
to the untreated control. (C) L-[3H]Arginine uptake normalized to control conditions after 72 h of 
arginine starvation in SKLMS1, MNNG and MG63. All experiments were done in biological triplicate. 
***p<0.001, **p<0.01, *p<0.05 







Figure 2. Cationic amino acid transporters’ expression in response to 
ASI-PEG20. Western blot analysis of the expression of CAT-1, CAT-2, 
CAT-3, y+LAT1, y+LAT2, b0,+AT and ATB0,+ in MG63, MNNG and SKLMS1 
after 72 h of ADI-PEG20 treatment. All experiments were done in biological 
triplicate. 
 
Uptake of [18F]AFETP increases after 
ADI-PEG20 treatment in vitro 
To determine if the translocation of CAT-1 to the 
plasma membrane following ADI-PEG20 treatment 
could be exploited for in vivo imaging, we measured 
the cellular uptake of the 18F-labeled amino acid 
AFETP in vitro. [18F]AFETP is structurally similar to 
L-histidine (Fig 4A). After 72 h of ADI-PEG20- 
induced arginine starvation, [18F]AFETP uptake was 
increased in the ADI-sensitive SKLMS1 and MNNG 
cell lines by 2.2 ± 0.4 and 1.5 ± 0.3 respectively, but not 
the ADI-resistant cell line MG63 where a 1.1 ± 0.1 fold 
change was observed with ADI-PEG20 treatment. 
These results are similar to those obtained with 
L-[3H]arginine and demonstrate that [18F]AFETP can 
be used as a surrogate for ADI-PEG20 response in cell 
lines that are sensitive to ADI-PEG20 (see Fig 4B). 
Finally, as there was not an increase in [18F]AFETP 
uptake in the MG63 ADI-PEG20-resistant cell line, 
[18F]AFETP may be a useful tool for determining 
when resistance to ADI-PEG20 evolves in vivo. These 
results trended in the same direction as those 
observed with L-[3H]arginine (Fig 1B, C). 
 [18F]AFETP-PET shows increased uptake 
after arginine depletion in vivo 
To test the ability of [18F]AFETP to monitor 
response to ADI-PEG20 in vivo, small animal PET 
studies were performed before and after ADI-PEG20 
treatment in a mouse model of arginine-dependent 
sarcoma. ASS1-negative SKLMS1 cells were 
xenografted into nude mice (5). Once tumors volume 
reached between 200-500 mm3, mice were treated 
with 320 IU/m2 (29.1 mg/m2) ADI-PEG20 once every 
three days. [18F]AFETP-PET imaging in mice with 
SKLMS1 tumor xenografts was performed 
immediately prior to starting ADI-PEG20 treatment 
and again at day 2 (after 1 ADI-PEG20 treatment) and 
day 4 (after 2 ADI-PEG20 treatments) to determine if 
[18F]AFETP uptake increased after systemic arginine 
depletion. In all animals, the tumors were clearly 
visualized above background tissues at baseline and 
after treatment with ADI-PEG20. These studies also 
demonstrated visually increased tracer uptake in the 
most of tumor xenografts at day 4 of ADI-PEG20 
treatment (Fig 5A, B). The average tumor to skeletal 
muscle ratios ± SD were 2.3 ± 0.6 on day 0 (prior to 
ADI-PEG20), 2 and 4, 3.0 ± 1.5 on day 2 of ADI-PEG20 
administration, and 3.2 ± 1 on day 4 of ADI-PEG20 
administration (Fig 5B; n=6 animals). The average 
tumor standardized uptake values (SUVs) ± SD were 
0.63± 0.06 on day 0, 0.72 ± 0.3 on day 2, and 0.74 ± 0.2 
on day 4.  
Changes in tumor size can affect PET 
measurements of standardized uptake values (SUVs) 
due to partial volume averaging, particularly when 
lesions are close to the resolution limits of PET. To 
address this potential confounding variable, the 
maximum axial dimensions of each tumor were mea-
sured (2 perpendicular measurements for each tumor) 
prior to beginning ADI-PEG20 administration (day 0) 
and again after 4 days of ADI-PEG20 treatment (day 
4). The tumors ranged in axial dimensions from 6x4 
mm to 17x12 mm on day 0 and from 7x4 mm to 18x13 
mm on day 4. The sums of the axial bidimensional 
measurements at day 0 and day 4 were compared, 
and the sum of measurements increased by an aver-
age of 6.4 ± 4% and 1.3 ± 1 mm by day 4. Given this 
small increase in size and the ~1.5-2 mm resolution of 
the small animal PET scanners used in this study, the 
observed increase in tumor size is unlikely to account 
for the difference in tumor to muscle ratios, which 
increased by an average of 36% by day 4. The 
apparent increase in tumor size in Fig. 5A is primarily 
due to increased [18F]AFETP uptake rather than 
increased tumor size. However, the present studies do 
not entirely exclude a contribution of increasing 
tumor size to the increased tumor to muscle ratios 
observed at day 4 of ADI-PEG20 therapy. 







Figure 3. CAT1 translocates to the plasma membrane in response to ADI-PEG20 treatment. (A) Immunofluorescence of CAT1, CAT-2, CAT-3, 
y+LAT1, y+LAT2, b0,+AT and ATB0,+ expression in SKLMS1 after 72 h of ADI-PEG20 treatment. Green is FITC secondary label, blue is DAPI. Control for the 
secondary antibody demonstrates no signal above autofluorescence. All images are at 60x. Scale bar, 20 μm. (B) Immunofluorescence of CAT1 expression in SKLMS1 
after 72 h of ADI-PEG20 treatment. Green is FITC secondary label, blue is DAPI, red is TRITC for wheat germ agglutinin (WGA) for plasma membrane staining. 
Images are merged to show overlap between CAT-1 translocation and plasma membrane staining. Scale bar, 20 μm.  






Sarcomas comprise over 60 different types of 
tumors, whose underlying biological diversity makes 
the development of a common and effective 
therapeutic across a wide range of subtypes very 
challenging. Historically, common mutations have 
included TP53, which occurs in only up to 50% of 
sarcomas, and PTEN loss, effecting only 30% of 
certain subtypes (32, 33). Only recently has it been 
demonstrated that approximately 90% of all sarcomas 
are ASS1-deficient; this discovery has led to the 
development of targeted therapies based on a 
common metabolic defect (5). As treatment of 
ASS1-deficient sarcomas with ADI-PEG20 monother-
apy allows only for the inhibition of cell growth, 
combination therapies based on the metabolic 
changes induced by ADI-PEG20 will need to be 
carefully developed (11, 12).  
Outside of the sarcoma field, ADI-PEG20 has 
been used in combination with other anti-proliferative 
drugs such as cisplatin, gemcitabine, and pemetrexed 
(34, 35). The success of these combinations has 
branched out into treating other cancers and is 
currently being assessed in clinical trials of advanced 
hepatocellular carcinoma, refractory small cell lung 
cancer, malignant pleural mesothelioma, prostate 
cancer, non-Hodgkin’s lymphoma, and acute myeloid 
leukemia (36, 37). As ASS1 is expressed in most 
normal tissues, therapeutically exploiting this 
enzymatic deficiency is highly desirable, as the 
toxicity to normal tissues should be less than other 
non-specific chemotherapies. The availability of an 
imaging biomarker suitable for preclinical and human 
use to assess the consequences and biological efficacy 
of arginine starvation is greatly needed to optimize 
the use of ADI-PEG20 for cancer therapy.  
In our study, the18F-labeled amino acid AFETP 
was used as a surrogate to monitor the upregulation 
of amino acids transport in response to ADI-PEG20 in 
an established preclinical animal model of sarcoma. 
Our overall findings are modeled in Fig 6. The in vitro 
studies examined the auxotrophic nature of 
ASS1-deficient cell lines, which are known to be more 
sensitive to ADI-PEG20 treatment. SKLMS1 and 
MNNG had a significant increase in L-[H3]arginine 
uptake after ADI-PEG20 treatment, as opposed to the 
insignificant change seen in the ASS1 expressing cell 
line MG63. To assess the mechanism underlying the 
increased arginine uptake, amino acid transporter 
expression was evaluated, with a slight increase in the 
expression of CAT-1 observed. In addition, IF was 
done to see if transporter transloca-
tion changes occurred upon ADI- 
PEG20 treatment, as localization may 
be more important than total 
expression for arginine uptake. Again, 
the results demonstrated that only 
CAT-1 translocated to the plasma 
membrane in response ADI-PEG20 
treatment. Although CAT-1 expressi-
on did increase in the ASS1 express-
ing cell line MG63, this increase in 
expression did not correlate with an 
increased uptake of L-[H3]arginine. 
This would suggest that CAT1 
expression and translocation may be 
controlled by sensing extracellular 
arginine concentrations, given the fact 
that MG63 can produce its own intra-
cellular arginine because of its high 
ASS1 expression. Further studies are 
needed to validate this hypothesis.  
 ADI-PEG20 induces a starvation 
response that leads to the destruction 
of various proteins in an effort to 
provide a source of arginine (5). As a 
result, we find that some of the 
cationic transports may be a target of 
this process. Despite the fact that 
there was a small decrease in the 
 
 
Figure 4. AFETP uptake increases in response to ADI-PEG20 in ASS1-deficient cells in 
vitro. (A) AFETP is structurally similar to histidine and is recognized by cationic and neutral amino acid 
transporters. The structure of the other cationic amino acids L-lysine and L-arginine are shown. (B) 
[18F]AFETP uptake normalized to control conditions in SKLMS1, MNNG and MG63 cell lines after 72 h 
of ADI-PEG20 treatment. All experiments were done in biological triplicate. ***p<0.001, **p<0.01, 
*p<0.05.  





expression of y+LAT2 and ATB0,+, this result does not 
appear to alter the ability of SKLMS1 or MNNG to 
accumulate [18F]AFETP or L-[3H]arginine intracell-
ularly. Altogether, this result could suggest that 
selective CAT-1 substrates inhibitors may be effective 
in improving the response to ADI-PEG20 for induced 
arginine starvation.  
 
 
Figure 5. Tumor uptake of AFETP increases in response to 
ADI-PEG20 treatment in vivo. (A) Two representative model mice at day 0 
(baseline) and day 4 of ADI-PEG20 treatment. In addition, signal was seen in the 
liver, bladder and testes. (B) Tumor to skeletal muscle ratios observed with 
[18F]AFETP in vivo. N=6 mice. ***p<0.001, **p<0.01, *p<0.05.  
 
PET use after treatment with ADI-PEG20 in 
ASS1-deficient cancers has only been evaluated in a 
few cases (38-41). The glucose analogue [18F]FDG does 
not appear to be useful for monitoring response to 
ADI-PEG20 treatment, as demonstrated by the 
decreased uptake in bladder cancer, which could be 
due to the rewiring of glucose metabolism by the 
treatment ADI-PEG20 and not due to tumor death (18, 
22). The uptake of [18F]AFETP is more closely related 
to the mechanism of cellular arginine uptake in 
response to ADI-PEG20 than is glucose metabolism 
measured with [18F]FDG. This study demonstrated 
that uptake of [18F]AFETP increased as opposed to 
decreased in response to arginine starvation. Given 
the possible heterogeneity of ASS1 expression in 
patients with multiple tumors and the unknown time 
frame of resistance due to ASS1 expression in patients 
with ASS1-deficient tumors, changes in [18F]AFETP 
uptake may be an early indication of tumor response 
to treatment. A potential limitation of [18F]AFETP for 
this application is the transport of this amino acid by 
both cationic and neutral amino acid transporters. 
Finally, formal clinical trials of [18F]AFETP and 
ADI-PEG20 will be needed to assess efficacy in 
patients with ASS1-deficient tumors.  
Materials and Methods 
Cell Culture 
Cell lines SKLMS1, MNNG and MG63 were 
purchased from ATCC (Manassas, VA). Cell lines 
were cultured at 37 oC and 5% CO2 in Modified Eagle 
Medium (MEM) (Life Technologies, Grand Island, 
NY) supplemented with 10% FBS and Penicillin- 
Streptomycin 100x (10,000 U/mL) (Life Technologies, 
Grand Island, NY).  
Western Blotting 
Whole-cell lysates were prepared using RIPA 
cell lysis buffer (Cell Signaling, Danvers, MA). Protein 
concentration was calculated using Bradford assay 
and 40 µg of protein was loaded and run on 
SDS-PAGE and transferred to polyvinylidene 
difluoride (PVDF) membranes (Bio-Rad, Hercules, 
CA). Membranes were blocked with 5% bovine serum 
albumin or low-fat milk and incubated with the 
following antibodies: CAT-1, CAT-2, CAT-3, 
y+LAT-1, y+LAT-2, b0,+AT, ATB0,+ (Santa Cruz 
Biotechnology, Dallas, TX).  
Immunofluorescence  
5000 cells were seeded in 2-well chamber slides. 
Cells were treated with 1 μg/mL ADI-PEG20 (Polaris 
Inc, San Diego, CA, USA) for 72 h. Cells were washed 
twice with 1x PBS and fixed with 4% PFA in 1x PBS 
for 10 min. Cells were washed three times with 1x PBS 
and blocked with 50% goat serum in 1x PBS for 30 min 
at 37 ºC. Primary antibodies were then added for 1 h 
at 37 ºC, washing three times for 5 min. Secondary 
antibodies were added for 1 h at 37 ºC. After a final 
three washes for 5 min, cells were mounted in Prolong 
Gold with DAPI (Vector, Olean, NY). Cells were 





imaged with an Olympus microscope and an 
Olympus DP72 camera. Camera settings were 128 ms 
for all FITC images. All images were assembled with 
Photoshop (Elements 13) and all changes to the FITC 
images were uniformly applied for figure clarity 
Photographs were equally adjusted in the green 
channel for printing clarity by changes “levels” so that 
the maximal intensity of the control figure was the 
given the maximal grey value. This was applied 
equally to the entire dataset. The nuclear stain in blue 
was adjusted non-uniformly as it is a nuclear marker 
to be used as a cellular special reference and not part 
of the experiment. 
Uptake Assays 
Cell lines were seeded at 1x105 cells per well in 
24-well plates (Corning Costar). The following assay 
buffers were used for the cell uptake studies: For 
L-[3H]arginine uptake assays, 7.4 MBq (200 μCi) of 
L-[3H]arginine (L-[ 2,3,4-3H]arginine monohydro-
chloride (1.48–2.59 TBq)/mmol, 37 MBq/mL, Perkin 
Elmer, Waltham, MA) in 2% ethanol/water stock 
solution was diluted in 15.5 mL of assay buffer (105 
mM sodium chloride, 3.8 mM potassium chloride, 1.2 
mM potassium bicarbonate, 25 mM sodium phosph-
ate dibasic, 0.5 mM calcium chloride dihydrate, 1.2 
mM magnesium sulfate, and 5.6 mM D-glucose 
adjusted to pH 7.4) at a concentration of 0.5 MBq/mL 
(13 μCi/mL). For [18F]AFETP uptake assays, 
18F-labeled amino acid AFETP was prepared as 
previously reported (29, 30), and a stock solution of 74 
MBq/mL (2 mCi/mL) of [18F]AFETP in water was 
diluted to a concentration of ~1.5 MBq/mL (40 
μCi/mL). 
 The cell uptake assays were initiated by 
discarding the culture media and then rinsing the cells 
twice with 2 mL of assay buffer at 37°C without 
radiotracer. Aliquots of assay buffer containing 
L-[3H]arginine (0.2 mL) or [18F]AFETP (0.4 mL) were 
then added to each well and allowed to incubate at 37 
°C for 5 min. The assay buffer containing the 
radiotracer was removed, and the wells were rinsed 
twice with 1 mL of ice-cold assay buffer without 
radiotracer. The cells were lysed by treating each well 
with 0.3 mL aliquots of aqueous 0.2% sodium dodecyl 
sulfate (SDS) in 0.2 M sodium hydroxide (NaOH) and 
then shaking the 24-well plates gently at room 
temperature for 45 min. Protein concentrations in each 
well were measured in triplicate (30 µL aliquots) 
using the Pierce bicinchoninic acid (BCA) protein 
assay kit method (Rockford, IL). 
 
 
Figure 6. Model of [18F]AFETP uptake in response to ADI-PEG20 treatment. In the presence of ADI-PEG20, extracellular arginine is converted to 
citrulline. In ASS1-deficient tumors, depletion of the extracellular pool of arginine causes an increase in the translocation of CAT1 to the plasma membrane. This 
allows for the PET tracer [18F]AFETP to be taken up into the cell, making this a useful tool for assessing biological response to ADI-PEG20 treatment. 





 For the [18F]AFETP assays, the radioactivity in 
150 µL of lysate from each well and in radioactive 
standards was measured as counts per minute (cpm) 
using a gamma counter (2480 Wizard2, Perkin Elmer). 
The cpm measurements were decay-corrected for 
elapsed time. For L-[3H]arginine assays, a 150 µL 
aliquot of lysate from each well was added to 2.5 mL 
of Biosafe II liquid scintillation fluid (Research 
Products International Corp, Mt. Prospect, IL) in 3 mL 
vials. The vials were then shaken vigorously and 
allowed to stand overnight. The radioactivity in the 
vials was then measured as cpm using a liquid 
scintillation counter (LS6500, Beckman Coulter Inc, 
Fullerton CA). For both [18F]AFETP and L-[3H] 
arginine assays, the cpm measurements were 
normalized to the protein concentration in each well. 
Assays were performed in triplicate and the values for 
the ADI-PEG20-treated cells were expressed as the 
percent uptake relative to the untreated condition for 
each cell line. The data is depicted as average of 
percent uptake used for statistical analysis. 
Small animal PET imaging 
All xenograft and small animal imaging 
experiments were approved by the Animal Studies 
Committee at Washington University School of 
Medicine. Male nude mice with subcutaneously 
implanted SKLMS1 tumor xenografts (n=6) under-
went small animal PET imaging immediately prior to 
ADI-PEG20 administration (day 0) and days 2 and 4 
after beginning ADI-PEG20. For each PET study, the 
mice were anesthetized with 1% isoflurane/oxygen 
followed by dynamic PET acquisition at 0-60 min after 
intravenous tail injection of 10-12 MBq of [18F]AFETP 
using INVEON and MicroPET Focus 220 systems. The 
animals were allowed to feed ad libitum prior to the 
[18F]AFETP studies. The animals were maintained at 
37 ºC during the study using a warming lamp. 
Computed tomography (CT) images were also 
acquired with the INVEON system.  
 The small animal PET data were analyzed by 
manually drawing 3-dimensional regions of interest 
(ROIs) over the tumor identified on the PET studies 
with correlation to CT to confirm the tumor location. 
ROIs for normal skeletal muscle were drawn over the 
lower extremity based on the CT images. The uptake 
data were expressed as mean standardized uptake 
values (SUVs) for each ROI. Tumor to skeletal muscle 
ratios were calculated by dividing the mean SUV in of 
the tumor by the mean SUV of the skeletal muscle ROI 
for each animal. The average of the SUVs in tumor 
and muscle and the average of the tumor-to-muscle 
ratios at 50-60 min after injection of [18F]AFETP were 
compared using 2-tailed t-tests. 
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